What is Lifesci Capital’s Estimate for SYRE FY2024 Earnings?

Spyre Therapeutics, Inc. (NASDAQ:SYRE) – Equities research analysts at Lifesci Capital boosted their FY2024 earnings per share estimates for shares of Spyre Therapeutics in a report issued on Tuesday, January 14th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($4.33) per share for the year, up from their prior estimate of ($4.41). The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.48) per share. Lifesci Capital also issued estimates for Spyre Therapeutics’ Q4 2024 earnings at ($0.94) EPS and FY2025 earnings at ($3.22) EPS.

Other equities research analysts also recently issued research reports about the stock. Wedbush reissued an “outperform” rating and issued a $65.00 target price on shares of Spyre Therapeutics in a research note on Monday. Guggenheim increased their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Robert W. Baird boosted their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Spyre Therapeutics currently has an average rating of “Buy” and a consensus price target of $54.83.

Spyre Therapeutics Stock Performance

NASDAQ:SYRE opened at $21.66 on Thursday. The stock’s fifty day moving average is $26.82 and its 200 day moving average is $28.15. The firm has a market capitalization of $1.11 billion, a PE ratio of -2.90 and a beta of 2.86. Spyre Therapeutics has a fifty-two week low of $20.07 and a fifty-two week high of $47.97.

Hedge Funds Weigh In On Spyre Therapeutics

Institutional investors have recently modified their holdings of the stock. Amalgamated Bank bought a new position in Spyre Therapeutics in the second quarter worth approximately $28,000. Quest Partners LLC bought a new position in shares of Spyre Therapeutics during the 2nd quarter worth $36,000. The Manufacturers Life Insurance Company increased its stake in shares of Spyre Therapeutics by 15.0% during the third quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company’s stock valued at $1,278,000 after buying an additional 5,678 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Spyre Therapeutics by 29.4% in the third quarter. JPMorgan Chase & Co. now owns 29,473 shares of the company’s stock valued at $867,000 after acquiring an additional 6,701 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Spyre Therapeutics by 127.0% during the 3rd quarter. SG Americas Securities LLC now owns 12,589 shares of the company’s stock worth $370,000 after acquiring an additional 7,044 shares in the last quarter. 80.39% of the stock is owned by hedge funds and other institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).